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Among Costa Ricans, CYP2C9*2 was also lower in the AM than 
in the CRM population (P < 0.05). Moreover, the frequency of 
CYP2C9*3 in the CRM, AM and AC groups was 3.6%, 2.1% and 
3.3%, respectively. CYP2C9*6 was not detected.
Conclusion: Present data support that the CYP2C9*2 frequency is 
lower in Amerindian populations than Caucasians, suggesting the 
importance of pharmacogenetic studies for optimizing drug dosages 
in different populations according to their ancestry.
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Introduction: The aim of this research was to study the preva-
lence of methylenetetrahydrofolate reductase (MTHFR) C677T 
gene polymorphismsand homocysteine concentration in male 
patients, European race, with mild to moderate essential hyper-
tension.
Patients (or Materials) and Methods: The investigations were per-
formed in 35 patients (mean age, 50.0 [5.9] years). All the patients 
had family history of essential hypertension. The higher prevalence 
of risk factors was revealed: smoking – 62.8% patients, overweight – 
71.4%, dyslipidemia – 48.6%. The following defeats of targets were 
diagnosed: left ventricular hypertrophy – 40% patients, ultrasonic 
signs of carotids atherosclerosis – 82.8% patients. To identify muta-
tions С677Т of a gene MTHFR polymerase chain reaction with the 
subsequent restriction amplifications was used.
Results: Genotypes by MTHFR were distributed as follows: homozy-
gotes C allele (СС genotype) was defined in 19 patients (55.9%); 
heterozygotes (СТ genotype) in 11 patients (32.3 %); homozygotes 
Т allele ( TT genotype) in 4 patients (11.8%). Homocysteine concen-
tration in patients with СС genotype was authentically lower than 
in patients with СT and TT genotype (11.34 [0.64] vs 15.33 [0.57] 
mkmol/L; P < 0.001).
Conclusion: Thus, in male patients, European race, with mild to 
moderate essential hypertension the prevalence of mutant allele T, 
determining the reduction of enzyme activity MTHFR, was 44.1%. 
The presence of mutant allele T was associated with a higher level of 
homocysteine concentration.
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Introduction: Raloxifene is a selective oestrogen receptor modulator 
commonly used for the treatment of postmenopausal osteoporosis. 
The drug is significantly associated with an increased risk of deep 
venous thrombosis and pulmonary embolism, probably because of 
its estrogenic effects on the coagulation and fibrinolytic systems. It is 
known that many drugs vary in potency and/or toxicity according to 
a dosing time. Because both the coagulation and fibrinolytic systems 
exhibit circadian rhythms, such adverse effects of raloxifene could be 
diminished by optimizing a dosing time. The aim of the present study 
was to investigate the effects of dosing time of raloxifene on markers 
of coagulation and fibrinolysis, as well as of bone metabolism.
Patients (or Materials) and Methods: Postmenopausal patients with 
osteoporosis were randomly allocated to 2 groups: 1 received 60-mg 
raloxifene once daily in the morning, whereas the other received 
60-mg raloxifene in the evening, for 12 months.
Results: In both groups, the activity of coagulation Factors IX and 
XII significantly increased after 12 months treatment compared with 
baseline. The activity of coagulation Factors II and V, and levels 
of markers of bone metabolism (ie, bone alkaline phosphatase and 
tartrate-resistant acid phosphatase 5b) decreased in both groups. 
The changes in these markers did not differ between the 2 groups. In 
contrast, the plasma concentration of plasminogen activator inhibi-
tor-1 increased in the patients with the morning dose but not in the 
patients with the evening dose.
Conclusion: Because the elevated concentration of plasminogen acti-
vator inhibitor-1 is shown to be associated with the risk of venous 
thromboembolism, these data suggest that the evening dose of ralox-
ifene is relatively safe dosage regimen.
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Introduction: Ponesimod is a selective sphingosine-1 phosphate 
(S1P1) receptor modulator currently in clinical development for 
multiple sclerosis and plaque psoriasis. Drug-induced prolongation 
of the QT interval can lead to torsades de pointes and sudden cardiac 
death. The aim of this study was to assess whether ponesimod has 
a negative QT/QTc effect as per ICH E14 guidance in a thorough 
QT/QTc study.
Patients (or Materials) and Methods: This was a single-center, dou-
ble-blind, placebo- and positive-controlled (400-mg moxifloxacin), 
parallel group with nested crossover, up-titration study in 116 healthy 
male and female subjects (58 subjects on ponesimod and 58 subjects 
on moxifloxacin/placebo). All subjects received placebo for ponesi-
mod on day –1. In treatment group A, ponesimod was administered 
orally once daily for 22 days (10 mg on days 2–4, 20 mg on days 5–7, 
40 mg on days 8–12, 60 mg on days 13–15, 80 mg on days 16–18, 
and 100 mg on days 19–23). In addition, subjects received placebo 
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for moxifloxacin on day 1 and day 24. In treatment group B, placebo 
for ponesimod was administered once daily for 22 days (days 2–23). 
In addition, subjects received a single oral dose of moxifloxacin 400 
mg either on day 1 or day 24. Replicate ECGs were to be extracted 
from the continuous digital 12-lead ECG recording over 12 hours. 
Primary end point was the baseline-adjusted, placebo-corrected 
effect of individual nonlinear corrected QT intervals (Δ Δ QTcI) on 
day 12 (40 mg) and on day 23 (100 mg). The relationship between 
plasma concentrations of ponesimod and metabolites and Δ Δ QTcI 
was assessed by applying a linear mixed effects modeling approach.
Results: Ponesimod caused a small QTc prolongation, with a mean 
peak effect on Δ Δ QTcI of 6.9 ms (upper bound of the 2-sided 90% 
CI, 11.3 ms) on 40 mg and 9.1 ms (upper bound of the 2-sided 90% 
CI, 14.0 ms) on 100 mg. However, upon extrapolation to steady-state 
concentrations reached with 20-mg ponesimod, the upper bound of 
the 2-sided 90% CI would be below 10 ms, and should result in a 
negative study for doses of 20-mg ponesimod or lower. There was no 
relevant increased incidence of QTcI outliers, either as absolute or 
change from baseline, and QTcI > 480 ms or QTcI increase > 60 ms 
from baseline was not observed with ponesimod. Ponesimod did not 
affect the PR or QRS intervals. Assay sensitivity was demonstrated by 
moxifloxacin QTcI response with a mean peak effect on Δ Δ QTcI of 
11.8 ms (lower bound of the 2-sided 90% CI, 9.0 ms).
Conclusion: Ponesimod at doses of 40 mg and 100 mg causes a 
small QTc prolongation. However, based on the concentration-effect 
relationship no clinically relevant effect on QTc interval is expected 
for a dose of 20 mg, the highest selected dose for Phase 3.
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Introduction: Hypoxia is associated with pro-inflammatory condi-
tions and increased risk of cardiovascular diseases. The transcription 
factors hypoxia-inducible factor (HIF)-1 and HIF-2 are known to 
have central roles in oxygen and energy homeostasis. Recent studies 
have shown that HIF-2α is deacetylated and activated by Sirtuin 
(Sirt)1, a nicotinamide adenine dinucleotide (NAD)-dependent 
deacetylase, suggesting that Sirt1 may be involved in resistance to 
hypoxic stress. The aim of our pilot study is to investigate the acute 
role of Sirt in adaptation to hypoxic conditions.
Patients (or Materials) and Methods: Five healthy volunteers inhaled 
a gas mixture of 10% oxygen in nitrogen for 4 to 6 hours. Blood 
samples were taken 2, 4, 6 to 8, and 24 hours after start of inhalation. 
Erythropoietin levels were measured in plasma, and hemoxygenase 1 
(HO-1), nicotinamide phosphoribosyltransferase (Nampt) and Sirt 
levels in peripheral blood mononuclear cells (PBMCs) by Western 
blot and qPCR.
Results: During inhalation of the 10% oxygen gas mixture, paO2 
levels decreased from a mean of 90 mm Hg to 50 mm Hg. Mean 
erythropoietin levels increased from 6.6 to 11.7 mU/mL 6 to 8 hours 
after the start of inhalation. Western blot analysis showed increased 
expressions of HO-1 and Sirt3 after 6 hours. The expression of the 
Sirt substrate Nampt was also increased after 6 and 24 hours. In 
contrast, only a small increase in Sirt1 and Sirt3 mRNA was detected. 
Sirt2 mRNA or protein expression was not altered following hypoxia.
Conclusion: Systemic hypoxia increases Sirt3 protein expression in 
PBMC. This suggests that histone deacetylation of hypoxia-inducible 
factors are affected by changes in Sirt expression in diseases with 
intermittent hypoxia. Drugs targeting Sirt may thus influence adap-
tation to acute hypoxic episodes such as sleep apnea syndrome or 
chronic hypoxic conditions.
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Introduction: In patients undergoing coronary artery bypass graft-
ing (CABG), ischemia-reperfusion (IR) damages myocardial tissue. 
Postoperative plasma troponin is a biomarker of myocardial injury 
and is associated with an adverse outcome. In animals, dipyrida-
mole reduces reperfusion injury by inhibition of the equilibrative 
nucleoside transporter (ENT) and subsequent increase in extracel-
lular adenosine (an activator of intracellular prosurvival pathways). 
In humans, oral dipyridamole significantly inhibits ENT. Cellular 
uptake of adenosine is reduced in subjects with reduced adenosine 
monophosphate deaminase 1 (AMPD1) activity. We hypothesized 
that oral dipyridamole limits myocardial IR-injury in patients under-
going CABG surgery and that this protection is limited to those with 
normal AMPD1 activity.
Patients (or Materials) and Methods: In a double-blind trial, 94 
patients undergoing elective CABG were randomized to pretreat-
ment with either dipyridamole retard (200 mg BID for 3 days) or 
placebo. Patients abstained from caffeine for at least 24 hours. The 
primary end point: plasma troponin-I at 6, 12, and 24 hours after 
CABG (high sensitivity assay, Siemens). Secondary end points bleed-
ing, arrhythmias 24 hours’ postoperatively, the need for prolonged 
inotropic support, and prolonged ICU stay. In all patients, AMPD1 
34C> T variants (CC: normal activity; CT and TT: reduced activity) 
was determined.
Results: Seventy-nine patients were included in the per-protocol 
analysis (46 placebo). Treatment arms did not differ with respect to 
age, gender, cardiovascular medication, cardiovascular risk factors, 
or aortic clamping time. Troponin concentrations increased from 0 
(0–0) to maximally 3.4 (2.4–5.5) in placebo and 3.7 (2.7–6.1) μ g/L 
at 6 hours after reperfusion (median with interquartile range; P > 
0.5 for comparison between treatment arms, mixed model analysis 
after log transformation).This increase in troponin was correlated 
with aortic clamping time (r = 0.3, P < 0.01, Spearman). As for the 
primary end point, secondary end points did not significantly differ 
between the 2 study arms. Analysis restricted to the AMD1 CC vari-
ant provided similar results.
Conclusion: Dipyridamole before CABG does not prevent the rise 
in troponin, regardless of AMPD1 genotype. We confirmed a role 
for IR in this measure of cardiac injury. Therefore, dipyridamole 
does not seem an effective therapy to prevent ischemia-reperfusion 
injury in humans.
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